Brief: Yichang Hec Changjiang Pharmaceutical Receives NMPA Approval Related To Registration For Domestic Production Of Insulin Aspart 30 Injection
19/02/2021 14:46
Feb 19 (Reuters) - YiChang HEC ChangJiang Pharmaceutical Co
Ltd 1558.HK :
* YICHANG HEC CHANGJIANG PHARMACEUTICAL- RECEIVED NMPA
APPROVAL
RELATED TO REGISTRATION FOR DOMESTIC PRODUCTION OF INSULIN
ASPART 30 INJECTION
Source text for Eikon: ID:
Further company coverage: 1558.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Yichang Hec Changjiang Pharmaceutical Co
See all newsBrief: Yichang Hec Changjiang Pharmaceutical Says Exchange Approved Withdrawal Of Listing Of H Shares
Brief: Yichang Hec Changjiang Pharmaceutical Says Encofosbuvir Tablets (0.3G) Approved For Launch By NMPA
Brief: Yichang HEC Changjiang Pharmaceutical Updates On Filing With Listing Committee
Brief: YiChang HEC Changjiang Pharmaceutical Says Sunshine Lake Pharma To Enter Licensing Agreement
Brief: YiChang HEC Changjiang Pharmaceutical Posts HY Revenue RMB2,454.8 Million